Peptides for Muscle Growth: Where the Human Evidence Ends

A muscle-building claim should answer a fairly ordinary question: will someone become stronger? For peptides for muscle growth, the human evidence answers a narrower question. Pharmaceutical tesamorelin trials recorded changes in lean mass, and a later analysis found selected changes on muscle scans. Those findings do not establish better strength or everyday physical function. A scan, inconveniently for the headline, cannot lift anything.

That distinction matters whether the goal is keeping up with training or lifting a suitcase into an overhead compartment. Tesamorelin deserves attention because researchers actually examined human muscle—not simply because it acts on growth-hormone signalling. But the strongest relevant work involved adults living with HIV and excess abdominal fat. Following that research from the original trials to a later look at their scans reveals exactly where a body-composition result becomes a much harder question about what a person can do.

Research Confidence

★★★☆☆ — Human randomized trials recorded lean-mass changes over 26 weeks in adults with HIV-associated abdominal fat accumulation. The muscle-specific evidence comes from a later, selected analysis of 193 tesamorelin responders and 148 placebo recipients. It measured muscle images rather than strength, with predominantly male participation.

Study Snapshot

• Study type: Exploratory secondary analysis of muscle scans from placebo-controlled trials
• Participants: 193 tesamorelin responders and 148 placebo recipients living with HIV
• Duration: 26 weeks
• Measured: Muscle density and cross-sectional area on CT scans
• Found: Psoas area changed by +0.4 versus −0.1 cm²; other total-muscle-area comparisons missed the analysis’s significance threshold
• Funding: NIH support; manufacturer supplied trial data and participated in authorship; authors declared no conflicts

Why This Matters: Muscle Size and Useful Strength Are Different Questions

For someone concerned about preserving muscle through midlife, the useful question is what remains possible: carrying luggage, rising from a low chair or continuing a familiar workout. Bigger muscles, less fat within muscle and better physical performance are related research questions, but each requires its own test.

A conversation about changing strength can therefore distinguish what a scan records from what a person can lift or comfortably do. Sensible expectations begin with naming the outcome, rather than accepting “muscle benefits” as a complete description.

The same distinction matters across healthy-ageing research: a change in a body measurement and a change in daily life deserve separate attention. To understand tesamorelin’s place here, start with what its original trials were built to measure.

The trials began with abdominal fat, not gym performance

Abdominal fat was the main outcome in the two randomized, placebo-controlled trials reported in the FDA’s March 2025 prescribing information. Random assignment means chance determined who received the study drug or placebo.

Adults aged 18–65 with HIV-associated abdominal fat accumulation received the original pharmaceutical formulation, supplied as 1-mg vials, at 2 mg by daily subcutaneous injection—under the skin—for 26 weeks. These are trial-design details, not a regimen for readers.

The label reports randomized totals of 412 and 404, although its listed second-trial arm totals sum to 396. That discrepancy remains unresolved in the supplied record. Completion was 80% and 74%.

Lean mass increased by 1.3 kg versus a 0.2-kg decrease in one trial, and by 1.2 kg versus a 0.03-kg decrease in the other. Lean mass includes more than skeletal muscle, including body water; kilograms gained cannot simply be renamed kilograms of new muscle.

The US approval concerns excess abdominal fat in adults with HIV-associated lipodystrophy—an altered pattern of body fat—not muscle growth or weight-loss management. The Canadian register documents a historical indication, not verified current marketing status.

A second look at the scans changed the question

The next step moved closer to muscle itself. Adrian and colleagues’ exploratory analysis revisited CT scans, which use X-rays to show slices through the body. Researchers assessed muscle area and density, an imaging measure used to examine fat within muscle.

Participants had received the parent trials’ pharmaceutical tesamorelin regimen described above or placebo. Crucially, researchers selected tesamorelin recipients who had already met a specified abdominal-fat response. They did not keep everyone originally assigned to tesamorelin in this comparison.

For the psoas, a deep muscle involved in hip movement, the reported area changes met the analysis’s statistical threshold: p<0.005. Other total-muscle-area comparisons did not. That probability test addresses statistical evidence; it cannot say whether someone would notice a difference when lifting or climbing.

Presenting this responder-selected analysis as proof of general muscle-building performance asks the study to do a job it was never designed to do. The participants had no reported strength or everyday-function tests in this analysis. The scan got a follow-up; the suitcase still awaits its trial.

These scans also came from the earlier trial populations. They add a different view of the evidence, rather than an independent replication.

Safety evidence came from a different kind of trial

Safety and metabolic outcomes were the focus of Clemmons and colleagues’ double-blind randomized trial in 53 adults with type 2 diabetes, eligible from age 50. “Double-blind” means participants and investigators did not know the assigned treatment during the trial.

The groups received placebo or lyophilized—freeze-dried—tesamorelin at 1 or 2 mg by daily subcutaneous injection for 12 weeks, followed by four weeks of safety follow-up. Group sizes were 16, 18 and 19.

The primary endpoint, meaning the main planned outcome, was insulin response after a glucose drink. There was no significant overall treatment difference, nor significant differences in weight, BMI, body-fat percentage or waist circumference.

Completion was 69%, 78% and 79%; adverse events occurred in 50%, 39% and 58%, respectively. No serious events were reported. The manufacturer sponsored the trial; a manufacturer-employed coauthor and paid consultancy were disclosed.

The FDA label separately warns about fluid retention, glucose intolerance and elevated IGF-1, a growth-related hormone signal. These records answer specific safety questions, not whether peptides as a group are safe for muscle growth. The research-peptide guide provides background on the distinction between research materials and clinical evidence.

What This Tells Us About Women Specifically: Menopause Was Not Reported

Women accounted for approximately 13% of the muscle-imaging analysis, calculated from its rounded male percentage. The parent trials were approximately 14% and 16% female, also derived from rounded figures. Muscle results were not separated by sex, and menopausal status was unreported.

The supplied records do not establish whether hormone therapy was accounted for. In the diabetes trial, women were eligible, but the demographic table could not be resolved during the research phase; a female percentage is therefore unavailable here.

For a perimenopausal or postmenopausal reader, these omissions matter: the studies cannot distinguish outcomes across those life stages. Men without HIV also fall outside the population behind the central imaging findings.

Research Use And Availability

Nuforme supplies tesamorelin as a research material in Canada, designated for research use only, not human consumption. The pharmaceutical formulations in these trials are distinct from that material. Nuforme also lists CJC-1295 No DAC + Ipamorelin; no completed muscle-growth trial of that exact combination was verified in this review. A research-use label does not authorize human use or itself establish permission to import or sell a product.

Final Thoughts: Strength Needs Its Own Trial

The evidence supports investigating tesamorelin’s effects on muscle composition, rather than recommending peptides generally for greater strength.

The concrete edges are substantial: the muscle comparison selected abdominal-fat responders, some scans were unavailable, and strength and daily function were never measured. A separate dropout or adverse-event analysis was not provided for that imaging subset. Manufacturer participation also matters when weighing the record: the imaging paper used manufacturer-supplied data and included manufacturer authors, while the label is sponsor-prepared.

Confidence would rise with a randomized trial that keeps all assigned participants in the analysis, measures strength alongside scans, includes adequate female participation and records menopause and hormone therapy. The next useful answer is whether people can do more—not simply whether an image changes.